Treatment for Brain Metastases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Brain Metastases+2 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new imaging agent to see if it can detect which patients are responding to brain cancer radiation therapy, and to track changes in the brain metastases over time.

Eligible Conditions
  • Brain Metastases
  • Cancer Brain Metastases
  • Metastatic Brain Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: through study completion, an average of 1 year

baseline
Compare change of SUV metrics of 18F-fluciclovine PET
Compare change of SUV metrics of contrast-enhanced MRI
Year 1
Change in sensitivity for MRI
PET/CT scan
Change in the standardized uptake value (SUV) parameters

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

20 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

Baptist Health South FloridaLead Sponsor
43 Previous Clinical Trials
7,752 Total Patients Enrolled
Blue Earth DiagnosticsIndustry Sponsor
27 Previous Clinical Trials
2,571 Total Patients Enrolled
Rupesh R Kotecha, MDPrincipal InvestigatorMiami Cancer Institute (MCI) at Baptist Health, Inc.
2 Previous Clinical Trials
274 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a confirmed diagnosis of brain metastases with at least one untreated lesion >2 cm in maximum diameter.
You are female or male, age ≥18 years.
You have a plan for SSRS that is consistent with the treatment team's goals and objectives.
You are of childbearing potential.